<?xml version='1.0' encoding='utf-8'?>
<document id="24624624"><sentence text="[New oral anticoagulants: pharmacological data to know for clinical practice]." /><sentence text="New oral anticoagulants target specific factors in the coagulation cascade by directly inhibiting thrombin for dabigatran and Factor Xa for -xatrans"><entity charOffset="111-121" id="DDI-PubMed.24624624.s2.e0" text="dabigatran" /></sentence><sentence text=" Pharmacological progresses with these anticoagulants allow the use of fixed doses without any therapeutic drug monitoring" /><sentence text=" Their pharmacokinetic specificity is the key role of the transporter proteins P-glycoprotein (P-gp) for all these drugs and the metabolism mediated by CYP3A4 for -xabans" /><sentence text=" Dose adjustment is recommended for decreasing creatinine clearance or in case of drug-drug interaction"><entity charOffset="47-57" id="DDI-PubMed.24624624.s5.e0" text="creatinine" /></sentence><sentence text=" New oral anticoagulants are promising but their safety needs further investigations in particular populations such as elderly patients, patients with renal or hepatic impairment, or patients on polymedication" /><sentence text="" /></document>